Full-Time

Assay Development Scientist

Profiling Development

Posted on 6/19/2025

Nomic

Nomic

51-200 employees

high-throughput proteomics platform employing nELISA

No salary listed

Montreal, QC, Canada

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Ph.D. or Master of Science in Bio-Engineering or other biotechnology-related field
  • 5+ years of hands-on experience in assay development, ideally within a biotech or life sciences company
  • Strong technical foundation in fluorescence-based bioassays, including experience with conjugation chemistry and fluorescent labeling strategies
  • Proficiency with techniques such as enzyme-linked immunosorbent assay, flow cytometry, bead-based assays, bioconjugation and purification, spectroscopy, or molecular biology
  • Experience working with complex biological samples and developing assays that account for matrix variability and real-world conditions
  • Familiarity with biotech research and development or manufacturing standards (for example, Good Laboratory Practice, Good Manufacturing Practice) and ability to analyze assay performance data to drive improvements
  • Clear, collaborative communication and a track record of managing projects across diverse teams
Responsibilities
  • Assay Development & Quality Control – Design, validate, and optimize proteomic assays and corresponding QC strategies to ensure robustness, sensitivity, and scalability across nELISA workflows
  • Fluorescent Labeling Optimization – Evaluate and improve conjugation chemistries, dye performance, and amplification strategies to maximize signal quality in complex biological matrices
  • Detection Method Optimization – Characterize and enhance flow cytometry and other optical detection techniques to meet performance targets and spectral requirements
  • Sample Diversity & Integration – Develop and validate protocols for diverse sample types, working with Automation to scale and integrate them into high-throughput workflows
  • Cross-functional Collaboration – Drive assay development from concept through deployment in a collaborative, fast-paced environment. Support root cause investigations, continuous improvements, and protocol handoffs to the Profiling team

Nplex Biosciences develops proteomics tools using nanotechnology, including the nELISA platform for high-throughput protein measurement. The platform uses DNA nanotechnology to identify proteins on micron-sized beads, enabling miniaturized, highly parallel immunoassays. It differentiates itself by combining DNA-based protein identification with bead-based assays and a scalable, cost-efficient workflow that lowers the cost of antibody-based proteomics. Its goal is to provide a reliable, scalable proteomics platform that supports drug discovery, biomarker discovery, and personalized medicine.

Company Size

51-200

Company Stage

Series B

Total Funding

$60.1M

Headquarters

Montreal, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Omni 1000 democratizes proteome-wide profiling for drug discovery and biomarker validation.[5]
  • $42M Series B September 2024 funds commercial expansion amid rising demand.[5]
  • Context-specific ~300-protein panels enable targeted discovery without multiplexing limitations.[2]

What critics are saying

  • Olink's Explore HT delivers 6000+ proteins, capturing larger pharma budgets.[1]
  • SomaScan's 11,000-protein aptamer technology erodes biomarker discovery market share.[1]
  • Post-Series B cash burn exceeds revenue as manufacturing scales in 2026.[1]

What makes Nomic unique

  • nELISA technology enables 1000-plex protein measurement at $50 per sample affordably.[5]
  • DNA-barcoded beads decode protein identity on standard flow cytometers seamlessly.[3]
  • End-to-end service model compatible with existing lab workflows and automation.[4]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

4%

2 year growth

1%
Yahoo Finance
Sep 19th, 2024
Nomic® Secures $42M in Oversubscribed Series B to Expand Access to Protein Profiling

MONTREAL, September 17, 2024--Nomic Bio ("Nomic"), the Protein Profiling company, today announces the completion of an oversubscribed $42 million Series B funding round. The fresh capital will enable Nomic to accelerate the expansion of its commercial operations, further invest in advancing its state-of-the-art protein profiling platform, and broaden its transformative offerings to meet growing demand.

BetaKit
Mar 18th, 2020
11 Canadian companies in Y Combinator’s Winter 2020 Demo Day

This week, Y Combinator (YC) held its Winter 2020 Demo Day, the 30th for the Silicon Valley incubator. To minimize health concerns during the COVID-19 outbreak, YC opted to host the demo day online. For this cohort, 16 Canadian startups participated.

TechCrunch
Mar 17th, 2020
All the companies from Y Combinator’s W20 Demo Day, Part IV: Healthcare, Biotech, Fintech and Nonprofits

Y Combinator’s Demo Day was a bit different this time around.

INACTIVE